Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF).

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) was featured today in the 420 with CNW by CannabisNewsWire. A recent study by the University of Connecticut and Georgia State University found that medical marijuana legalization seems to be encouraging people to engage more in sexual activities. The researchers also found that since medical marijuana policies were enacted, there has been a decrease in the consumption of contraceptives, and an increase in the number of children born.

Willow Biosciences (TSX: WLLW) (OTCQB: CANSF), an emerging biotechnology company focused on the biosynthetic production of cannabinoids, is well positioned to disrupt the cannabis industry supply chain by utilizing its ability to provide biosynthetically derived cannabinoids. To view the full article, visit http://cnw.fm/DbQt5.

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (OTCQB: CANSF), closed Monday's trading session at $0.44, up 1.1494%, on 400 volume with 4 trades. The average volume for the last 3 months is 7,925 and the stock's 52-week low/high is $0.400999993/$2.1775.

Recent News

• 420 with CNW – Study Finds People Have More Sex When Medical Marijuana is Legalized
• 420 with CNW – Study Finds People Have More Sex When Medical Marijuana is Legalized
• Absence of Federal Regulations Exposes CBD Industry to Class Action Lawsuits

Jerrick Media Holdings, Inc. (OTC: JMDA)

The QualityStocks Daily Newsletter would like to spotlight Jerrick Media Holdings, Inc. (OTC: JMDA).

After six years of strategic focus and relentless work, Jerrick Media Holdings Inc. (OTC: JMDA), a holding company that creates technology+, has built a distinctive technology platform that ranks among the top online creator platforms in the digital world. Designed to develop, empower, and engage content creators in a cost-effective way, Jerrick’s flagship product, Vocal, has grown to be one of the top online creator platforms, accruing hundreds of new creators daily. Also today, NetworkNewsWire released a report on the company detailing how Vocal, the company’s flagship product, is a proprietary, long-form, digital publishing platform. To view the full article, visit http://nnw.fm/k92hY

Jerrick Media Holdings, Inc. (OTC: JMDA) develops technology-based solutions to solve digital problems. Through the combination of design, thought and data analysis, the company builds products that influence a worldwide audience.

Jerrick’s flagship product is Vocal, a proprietary long-form digital publishing platform that provides storytelling tools and engaged communities for creators to get discovered and fund their creativity.

Vocal

Designed to develop and cost-effectively engage content creators, the Vocal platform enables its over 500,000 registered content creators to reach an engaged audience and monetize their content. In addition to providing relevant content, Vocal’s technology is centered on efficiency and scalability through its niche digital communities, as well as output through its data-driven distribution strategy.

Vocal partners with content creators and brands that recognize difficulties inherent in the digital advertising space and that can benefit from branded content marketing opportunities available on publishing platforms like Vocal.

All content available on Vocal is created within the platform’s custom editor and published on one of Vocal’s embedded genre-specific communities, spanning topics that range from food to wellness, beauty, technology and more.

In May 2019, Jerrick launched Vocal+, its premium subscription membership program. Vocal+ members pay a membership fee for premium value-added features, including receiving increased earnings for their content, reduced platform processing fees for tips received, a Vocal+ badge on their creator page, access to new features on the Vocal Platform, and other rewards. Creators can sign up for free or upgrade to Vocal+, available for purchase on either an annual or monthly subscription basis.

Vocal for Brands

Vocal for Brands is an in-house creative studio that generates actionable data from bespoke native advertising campaigns. Vocal for Brands partners with direct-to-consumer (DTC) to create beautiful, campaign-optimized stories on Vocal that build brand affinity, trust and drive results.

Additionally, Jerrick provides a Managed Services offering to business-to-business (B2B) and business-to-consumer (B2C) product and service brands which encompasses a full range of digital marketing and e-commerce solutions. Managed Services includes the setup and ongoing maintenance of clients’ websites, Amazon and Shopify storefronts and listings, social media pages, search engine marketing, and other various tools and sales channels utilized by e-commerce sellers for sales and growth optimization. In addition to partnering with Managed Services clients, the company offers a range of la carte services.

Growth Strategy

Upon the consummation of its anticipated listing on the Nasdaq Capital Market, Jerrick intends to change its official company name to “Creatd, Inc.,” subject to stockholder approval.

This rebranding will initiate Jerrick’s go-forward growth strategy and its plans to expand its offerings and provide technology products and resources for creators to help transform their ideas into reality. The strategic plan is designed to greatly increase Jerrick’s potential market value via a plethora of new revenue streams.

Creatd will focus on a community of creators that number more than 2.5 billion users, for which it will offer democratized, transparent platforms for distribution, sentiment, resources and monetization. The company’s agile development process will rely on a combination of bleeding-edge technology that eliminates barriers and creates efficiencies. Superior design thinking and data analysis will allow Creatd to expand its digital footprint to a global community.

Creatd will partner with a community of technology collaborators and sophisticated investors who collaborate to provide technology solutions for creators, brands and their respective audiences. The company’s solutions, business processes, technology platforms and design theories will lend themselves to application opportunities on a global scale.

History & Management

Jerrick was founded in 2012. Initially a private media company providing online content through a portfolio of brands, Jerrick’s needs quickly outpaced its initial technology and product offering. In 2015, Jerrick partnered with Thinkmill, a premiere, Australia-based product design and development group to create a content management system (CMS) for its brands; that system evolved into the company’s flagship product, Vocal.

Today, Jerrick’s management team is an impressive group of abstract thinkers united by their passion to solve problems. Leading the team are founder and CEO Jeremy Frommer, and Justin Maury, Jerrick’s president and head of product.

Frommer’s career includes two decades in the financial technology industry, working as a hedge fund and portfolio manager, as well as on the sell-side of the financial industry. Frommer started NextGen Trading, a software development company building proprietary equity trading platforms. NextGen was acquired by Carlin Financial Group of which Frommer became CEO. RBC Capital Markets Corporation eventually bought Carlin. At RBC, Frommer was managing director, head of the Global Prime Services group and a member of the RBC Global Equities Operating Committee.

Maury joined Jerrick in 2013, bringing with him 10 years of experience in the creative industry. Since partnering with Frommer to establish Jerrick, Maury led the company’s product development for more than four years. His passion for the creative arts and technology ultimately yielded the vision for Vocal. During the Jerrick’s early formative years, Maury was a driving force in creating the vision, design and architecture for the Vocal platform and managing the oversight of technology development.

Jerrick Media Holdings, Inc. (JMDA), closed Monday's trading session at $3.90, even for the day, on 1,000 volume. The average volume for the last 3 months is 1,278 and the stock's 52-week low/high is $1.63999998/$5.00.

Recent News

• Jerrick Media Holdings Inc. (JMDA) Developed Proprietary Technology to Power its Best-In-Class Creator Platform
• Why Jerrick Media Holdings Inc. (JMDA) Is ‘One to Watch’
• Jerrick Media Holdings Inc. (JMDA) CEO Details Big Payoff to Early Sacrifices, Organization Prepared for Endurance in Weekly Update

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Virtual Investor Conferences and KCSA Strategic Communications today announced that the presentations from the January 9th Cannabis Industry Virtual lnvestor Conference are now available for on-demand viewing at VirtualInvestorConferences.com. Among the presentations is Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

• Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
• Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
• Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
• Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
• Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
• Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Monday's trading session at $0.8983, off by 2.4541%, on 71,803 volume with 109 trades. The average volume for the last 3 months is 49,172 and the stock's 52-week low/high is $0.839999973/$6.00810003.

Recent News

• Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing
• 420 with CNW – Italian Scientists Announce Discovery of Two New Marijuana Cannabinoids
• South Carolina Threatens to Crackdown on Companies Making Pet and Animal CBD Feeds

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

Cannabinoid science innovator MCTC Holdings Inc. (OTC: MCTC), doing business as Cannabis Global, Inc., announced the launch of Hemp You Can Feel™ Coffee based on its patent pending hemp extract infusion technologies. The coffee will become available to consumers later in January 2020. "The new product is based on our recently completed R&D efforts that resulted in our dual infusion clean label process that uses only natural ingredients and zero chemical additives,” CEO Arman Tabatabaei stated in a company press release (http://cnw.fm/87g3R). The single serving coffee pods will be in a 100% compostable format.

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

• Significantly improving bioavailability
• Allowing for ultra-high loading rates
• Enhancing customization of cannabinoid combinations
• Improved dosing precision
• Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

• The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
• Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
• Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
• Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Monday's trading session at $0.33, even for the day, on 1,282 volume with 7 trades. The average volume for the last 3 months is 10,477 and the stock's 52-week low/high is $0.075000002/$3.00.

Recent News

• MCTC Holdings Inc. (MCTC) Launches Hemp You Can Feel™ Coffee Based on Patent Pending Hemp Extract Infusion Technology
• New Year’s Holiday Revelries Show Importance of MCTC Holdings Inc. (MCTC) Cannabis Beverage Infusion Developments
• Sellers Say Newly Enacted CBD Law in New York is Good for Customers

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF).

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) is feeling positive about 2020 based on its unique “local to grower” drying-to-biomass storage capability and transportation of dried biomass to its extraction facilities. In addition, HTC’s patented Delta Purification™ technology recycles, reuses, and purifies the extraction ethanol used in the cannabidiol (CBD) extraction process, being designed to optimally manage and reduce any CBD waste losses by re-extracting all wastes the purified ethanol yields. Also today, CBDWire released a report on the company detailing how, just a year after the 2018 Farm Bill legalized industrial hemp, the market for hemp extract cannabidiol (CBD) is booming, and experts predict it will hit a whopping $20 billion by 2026. Most of this demand is driven by claims that the hemp extract is medically effective. Cannabidiol is said to be effective against a variety of illnesses, ranging from chronic pain and high blood pressure to anxiety.

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

• LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
• PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
• Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

• Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
• Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
• Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (OTCQB: HTPRF), closed Monday's trading session at $0.152, even for the day, on 1,976 volume. The average volume for the last 3 months is 3,139 and the stock's 52-week low/high is $0.100299999/$0.920000016.

Recent News

• HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) Positioned for Growth with Unique ‘Local to Grower’ Storage, Delta Purification™ Tech
• Company Files Patent for Water-Soluble CBD Delivery System
• Amid Extension into US, 2020 is Shaping Up as Banner Year for HTC Extraction Systems’ (TSX.V: HTC) (OTCQB: HTPRF) Cannabinoid Operations

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com (OTCQB: CIIX) CEO Warren Wang provided an update regarding the company and its CBD Biotech subsidiary in a recent SmallCapVoice.com interview (http://cnw.fm/v1kML).  To view the full article, visit http://cnw.fm/KDS7u

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Monday's trading session at $0.156, off by 2.50%, on 20,850 volume with 19 trades. The average volume for the last 3 months is 53,316 and the stock's 52-week low/high is $0.150000005/$0.550000011.

Recent News

• ChineseInvestors.com Inc. (CIIX) Anticipates Significant Opportunities in China for CBD, Hemp-Infused Cosmetic Products
• ChineseInvestors.com Inc. (CIIX) CEO Discusses CBD Initiatives on MoneyTV with Donald Baillargeon
• 420 with CNW – Overwhelming Demand Causes Recreational Weed Shortage in Illinois

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Precision medicine, an approach that seeks to understand the genetic makeup of a patient’s tumor in order to customize a drug targeting the particular gene type for each patient, offers tremendous potential for the treatment of a number of diseases. Predictive Oncology Inc. (NASDAQ: POAI), a data and artificial-intelligence-driven precision medicine company that develops models that predict tumor drug response, possesses a unique competitive advantage in this space, which Mordor Intelligence Inc. estimates will grow at a CAGR of 9.7%, reaching $84.6 billion by 2024 (http://nnw.fm/aLp0V).

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

• A database of clinically validated historical and outcome data from patient tumors
• An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
• A “smart” patient-derived tumor profiling platform
• An in-house bioinformatics artificial intelligence (AI) platform
• A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
• An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Monday's trading session at $2.495, off by 0.992063%, on 16,994 volume with 79 trades. The average volume for the last 3 months is 34,004 and the stock's 52-week low/high is $2.28999996/$8.50.

Recent News

• Predictive Oncology Inc.’s (NASDAQ: POAI) Disruptive Platform Overcoming Obstacles in Precision Medicine Industry
• Predictive Oncology Inc. (NASDAQ: POAI) Working to Create World’s First Comprehensive, Actionable Multi-Omic Data Set for Ovarian Cancer
• Predictive Oncology Inc. (NASDAQ: POAI) Announces Appointment of Pam Prior to its Board of Directors

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP)innovative DehydraTECH(TM) delivery platform is patented for all nonpsychoactive cannabinoids as well as for tetrahydrocannabinol (THC) and psychoactive cannabinoids. To view the full article, visit http://cnw.fm/84SZu. Also today, the company was highlighted in a publication from HempWireNews, examining how the 2018 Farm Bill was instrumental in the growth of the hemp/CBD sector. It made a clear distinction between marijuana and hemp, classifying cannabis with less than 0.3% THC as legal Industrial hemp. THC is the chemical that creates marijuana’s infamous high, and farmers planning on growing hemp had to meet that low level of this compound.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Monday's trading session at $0.415427, off by 5.5848%, on 199,395 volume with 111 trades. The average volume for the last 3 months is 106,868 and the stock's 52-week low/high is $0.3037/$1.6875.

Recent News

• Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Platform Boosts CBD Absorption Levels
• Maine Hemp Farmers Voice Concerns With Proposed State Law
• Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Posts Strategic Company Update

GP Solutions (OTC: GWPD)

The QualityStocks Daily Newsletter would like to spotlight GP Solutions (GWPD).

GP Solutions (OTC: GWPD), the developer of modular controlled-environment micro-farms, today announced that GrowPods may help farmers reduce risk and increase quality control. According to the update, indoor farms are susceptible to crop failure, and factors including temperature, humidity, oxygen, watering and feeding cycles need to be finely tuned to ensure a healthy crop. To view the full press release, visit http://nnw.fm/Hfnv4

GP Solutions (OTC: GWPD) is developing scalable farming systems for soil-less indoor organic farming. The company’s GrowPods are automated micro-farms that use hydroponic technology and unique soil systems to cultivate the highest-quality specialty leaf crops. The system is designed and engineered for ease of use, allowing users to farm year-round in any location of the world, supporting the company’s mission to provide customers with the ability to cultivate their own organic “superfoods.”

GrowPod Design & Function

GrowPod is a modular, stackable and mobile vertical growing environment specifically engineered to maximize yield and automation. GrowPods are available as a vertical pod, stacker pod or custom-built pod.

The Stacker Pod is a certified organic soil system that offers growers multiple levels of planting in order to maximize space and produce options with different fruits and vegetables. The Vertical Pod utilizes a vertical hydroponic system. It is affordable, scalable, efficient, automated and sustainable. The output provides customers with fresh and clean produce year-round in any climate. The Custom Pod is built to suit the farmer’s specific crop and grow goals.

Each 320-square-foot GrowPod container will have an annual production capability of up to four times that of outdoor growing methods, dramatically increasing profitability to the grower. The controlled environment of the GrowPod ensures efficient power and water usage in growing a wide range of horticultural and agricultural products in all environments and climates.

Thanks to a combination of hydroponic and certified organic soil systems, crop yields are higher, faster, and more consistent that conventional means. Customers can enjoy an average of eight higher yield crop cycles anywhere in the world.

GrowPod Features:

• Modular, stackable and mobile
• Fully insulated, food-grade shipping container
• Engineered for automation
• Efficient LED lighting
• Hydroponic or soil-based platforms
• Proprietary air and water filtration
• Climate-controlled
• Remote monitoring

GP Solutions also offers many services to its customers, including:

• Shipment and installation service of its shipping container farms
• On-site training
• Provision of custom planting and harvesting schedule
• Provision of growing supplies, seeds, nutrients, packaging, branding and repair materials
• On-site visits, on-call and scheduled maintenance, and re-supply
• Remote monitoring and automated control of environmental nutrients, environmental growth factors (PH, temperature, light) and circulation
• Technical assistance
• Consulting and custom facility systems design

Competitive Advantage

GrowPods allow cultivation to take place year-round, which maximizes ROI. The systems are sealed from outside pathogens, contaminants, pesticides, and the result is clean and robust crop production.

GP Solutions also has a line of remarkable new proprietary soil mixtures and nutrient lines which contain no animal products. These products are vital, as many other soils and additives can contain harmful pathogens and contaminants that can cause crops to become tainted or fail rigorous testing.

Global Solution

GP Solutions has partnered with the world’s leading food nonprofit companies, including Feeding America, Seeds of Hope, Habitat for Humanity, Meals on Wheels America, L.A. Kitchen, and Farm Bread, to help insecure communities take control of their own food dependence using container farms.

GP Solutions (GWPD), closed Monday's trading session at $1.00, even for the day, on 613 volume. The average volume for the last 3 months is 269 and the stock's 52-week low/high is $0.600000023/$21.00.

Recent News

• GP Solutions, Inc. (GWPD) Says that GrowPods May Help Farmers Reduce Financial Risk, Increase Quality Control
• GP Solutions, Inc.’s (GWPD) GrowPods May Help Reduce Foodborne Illnesses
• Over 48 Million Americans Get Sick and 3,000 Die Each Year From Foodborne Illness

Neutra Corp. (OTCQB: NTRR)

The QualityStocks Daily Newsletter would like to spotlight Neutra Corp. (NTRR).

Neutra Corp. (OTC: NTRR) on Friday announced a long list of its achievements for the past 12 months and looks forward to more positive results in 2020. Among Neutra’s reported accomplishments were the company’s addition of Dr. Scott E. Cherry, DO, MPH, FACOEM to assist in tapping into the sports performance market, as well as its VIVIS Acquisition. To view the full press release, visit http://cnw.fm/4pDcM

Neutra Corp. (OTCQB: NTRR) is an early-stage research and development company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.

Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.

Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to bring these products to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment and life for people around the globe.

Acquisitions

• VIVIS – Neutra continues to expand its market presence in the rapidly growing hemp-derived CBD market and recently acquired VIVIS, an emerging retail brand of hemp-based health and nutritional products. VIVIS’ hemp-derived CBD products are third-party certified as contaminant-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With VIVIS as the new retail face of Neutra, the company is expecting greater interest in its expanding portfolio of branded products moving to market.
• J3 Holdings – The signing of a letter of intent to acquire J3 Holdings includes the company’s land and warehouse, as well as a license to cultivate hemp and refine it into usable forms. Neutra has concentrated its early efforts developing business networks and on developing hemp-based CBD products, including supplements and creams. The latest move will enable the company to grow its own hemp supply, giving it more control over the quality of its ingredients.

Partners

• Surface to Air Solutions is the North American distributor of a patent-pending, water-based solution known as Purteq, a green technology that works similar to photosynthesis.
• ZeroBlast uses a durable, non-toxic, anti-microbial solution to eliminate all contaminates and kill germs on contact for a period of up to 90 days.

Leadership

Neutra president and CEO Sydney Jim provides strong executive leadership, a network of business contacts and experience implementing solid corporate strategy. Jim has a proven track record of adding value for public company shareholders. He founded Global Visionary Investments where operational support is provided to seven different companies and their subsidiaries. Jim was also the CEO of First Titan Energy, a microcap public company where he was responsible for restructuring the corporate structure, deal sourcing, and leading the company in mergers and acquisitions.

Dr. Scott Cherry is the company’s sports performance medical advisor. He is an energetic physician executive with a passionate focus on health, performance and prevention. Dr. Cherry received emergency medical technician training in the U.S. Navy, a bachelor’s degree in chemistry from Florida State University, medical degree from Nova Southeastern University, and a master’s degree of public health from Uniformed Services University F. Edward Herbert School of Medicine. Dr. Cherry has honed his skills in a variety of medical and executive positions spanning the U.S. Army and Navy, several Fortune 500 corporations, and major health care facilities over the past 20 years.

Neutra Corp. (OTCQB: NTRR), closed Monday's trading session at $0.0008, even for the day, on 90,960,048 volume with 135 trades. The average volume for the last 3 months is 22,649,701 and the stock's 52-week low/high is $0.0005/$0.063900001.

Recent News

• Neutra Corp. (NTRR) Announces Successful Year Full of Achievements
• Arkansas Hemp Conference Slated for Mid February
• New Task Force Aims to Develop Hemp Sampling and Analysis Standards

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) was featured today in the 420 with CNW by CannabisNewsWire. A recent study by the University of Connecticut and Georgia State University found that medical marijuana legalization seems to be encouraging people to engage more in sexual activities. The researchers also found that since medical marijuana policies were enacted, there has been a decrease in the consumption of contraceptives, and an increase in the number of children born.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees and culture of innovation. The company aims to grow the world’s best legal cannabis and become a leader in the global industry. Supreme Cannabis calls its Toronto Venture Exchange stock symbol, “FIRE,” a testament to the company’s passion for cannabis and obsession with quality.

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as one of Canada’s most premium cannabis producers, the company sees itself at the center of this global shift.

A key piece of Supreme Cannabis’ ability to fulfill its mission is its flagship brand, 7ACRES, a wholly owned subsidiary that operates a 440,000-square-foot hybrid cultivation facility in Kincardine, Ontario. 7ACRES is focused on building a core competency in scaled high-quality cannabis production. With a best-in-class cultivation facility producing a competitive product that fuels a leading premium brand, Supreme Cannabis has achieved a differentiated advantage in cultivation IP, products and branding. The company’s foundational investment in premium cultivation has secured it a leadership position in the industry as the Canadian market becomes more competitive and matures.

Since legalization, 7ACRES has brought five premium flower strains to market in Canada. The demand for 7ACRES product continues with the company’s most recent launch of Jack Haze, a new proprietary premium cultivar. The company’s first sativa-dominant strain, Jack Haze offers rare sensory characteristics, delivering high THC content with a terpinolene forward profile, including a complex aroma with notes of citrus, pine and warm spice. As it develops its next winning strain, 7ACRES continues to prioritize subjective quality. In the Canadian cannabis market, this approach has established 7ACRES as a well-known premium brand that commands premium pricing coast-to-coast.

In addition to 7ACRES, Supreme Cannabis has built a diversified portfolio of focused consumer-driven brands:

• Sugarleaf by 7AC – this new brand widens Supreme Cannabis’ product offerings and targets consumers who are looking for more refined, milder consumption experience as they discover their own cannabis taste preferences and desires. Product formats under this brand are focused on offering consumers elegant and convenient cannabis experiences.
• Blissco — dedicated to providing wellness focused consumers with premium cannabis products, education, and outstanding customer care. Blissco is focused on bringing its collection of premium whole-flower CBD oils to market.
• Truverra — focused on being a global leader in the development, production and marketing of hemp and cannabis-derived medicinal products with clinically proven efficacy. With over 25 SKUs sold online in the UK and Europe, Truverra is ideally positioned to address emerging international cannabis opportunities.
• Khalifa Kush Enterprises — formed through a prestigious international partnership with Khalifa Kush Enterprises (KKE) Canada, the Canadian counterpart to the popular U.S. cannabis brand KKE formed by Wiz Khalifa. Together, Supreme Cannabis and KKE Canada are developing and launching a lineup of premium cannabis products, including a future line based on the well-known Khalifa Kush strain.

Each of Supreme Cannabs’ brands and partnerships have been strategically identified and designed to support the company’s mission to enhance the lives of consumers through positive cannabis experiences. Equally important to delivering desirable consumer experiences is the infrastructure supporting the company’s brands and products. From seed to sale, supreme cannabis continues to build an impressive group of operating assets that serve key functions throughout the value chain:

• Cultivation – for starters, there is Supreme Cannabis’ foundational flagship asset, its 440,000-square-foot cultivation facility in Kincardine, Ontario. With over 600 employees, 24 grow rooms, and best-in-class processing equipment and procedures, this facility is expected to reach an annual production capacity of 50,000 kilograms in the near-term. In this purpose-built facility, the company grows small-batch high-quality cannabis from 10,000-square-foot grow rooms and completes a proprietary hang-dry for up to two weeks.
• Extraction – with the acquisition of Blissco in fiscal 2019, in addition to the Blissco wellness brand, Supreme Cannabis gained a 12,000-square-foot dedicated extraction facility in Langley, BC. This facility conducts both C02 and ethanol extraction and with the recent receipt of its oil sales license from Health Canada, it now produces Blissco branded CBD oils and expects to fill vaporizer pods for a partnership between the company’s 7ACRES brand and Pax Labs.
• Manufacturing – most recently, the company announced its 107,000-square-foot processing, packaging and manufacturing facility in Kitchener, naming the facility Supreme Cannabis Kitchener. In Q4 FY2020, the company expects to begin whole flower packaging and pre-roll manufacturing for Supreme Cannabis brands at the Kitchener Facility. In the long-term, in additional to processing its own inputs, Supreme Cannabis intends generate incremental revenue by packaging, distributing and branding third-party cannabis inputs from quality-focused cultivators.
• R&D and Product Testing – In Q1 FY2020, Supreme Cannabis closed the acquisition of Truverra and acquired a 5,000-square-foot facility licensed under Canadian Clinical Cannabinoids Inc. in Scarborough, Ontario (“Supreme Cannabis Scarborough”). Supreme Cannabis Scarborough provides R&D space for the company to test new products and develop medicinal science intellectual property. In the near-term, with the legalization of 2.0 cannabis products, this centre for innovation will be testing and bringing concentrate products to market under the 7ACRES brand.

Supreme is committed to continue to identify new opportunities to grow and strengthen its impressive portfolio of operating assets and brands and scale its strong Canadian business globally.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Monday's trading session at $0.37, off by 2.4776%, on 667,960 volume with 383 trades. The average volume for the last 3 months is 508,250 and the stock's 52-week low/high is $0.346799999/$1.7888.

Recent News

• 420 with CNW – Study Finds People Have More Sex When Medical Marijuana is Legalized
• 7ACRES Tour Video - Understanding Supreme's Premium Advantage
• Indiva Ships Sugarleaf by 7AC Pre-Rolls Nationwide

LiveWire Ergogenics Inc. (OTC: LVVV)

The QualityStocks Daily Newsletter would like to spotlight LiveWire Ergogenics Inc. (LVVV).

LiveWire Ergogenics Inc. (OTC: LVVV) was featured today in a publication from CBDWire, examining how, just a year after the 2018 Farm Bill legalized industrial hemp, the market for hemp extract cannabidiol (CBD) is booming, and experts predict it will hit a whopping $20 billion by 2026. Most of this demand is driven by claims that the hemp extract is medically effective. Cannabidiol is said to be effective against a variety of illnesses, ranging from chronic pain and high blood pressure to anxiety.

LiveWire Ergogenics Inc. (OTC: LVVV) is a forward-thinking company specializing in identifying and monetizing current and future trends in the health and wellness industry. The company recognizes significant potential in the multibillion-dollar cannabis industry and operates at the forefront for acquisition and management of licensed cannabis real estate locations and the research, development and commercialization of high-end products for distribution throughout California.

During the past two years, LiveWire has diligently researched, secured, designed and set up several fully compliant and permitted cannabis operations in locations in California, including a state-wide distribution license from the Bureau of Cannabis Control. The company is focused on acquiring compliant real estate properties for cannabis operations and entering into operation agreements and strategic alliances to build teams of carefully selected and vetted operators, horticulturists, extractors, distributors and establish research partnerships. Its current portfolio of cannabis operations consists of the following properties:

PODs and Distribution in Coachella, California

For the past year, LiveWire has operated high-tech, state-of-the-art production structures, or “PODs” for its cannabis nursery business. Coachella is also home to the company’s statewide distribution headquarters. Both entities operate under LiveWire’s majority owned subsidiary, GHC Ventures. The company is currently in the process to strategically centralize all operations at its recently acquired Paso Robles facility, Estrella Ranch.

Estrella Ranch in Paso Robles, California

Through its subsidiary, Estrella Ranch Partners LLC, LiveWire acquired a 265-acre historic ranch property in Paso Robles, Calif. Estrella Ranch has a longstanding history, once owned by George R. Hearst, the eldest grandson of the late William Randolph Hearst, developer of Hearst Communications, and is considered among the finest ranches in California and the gem of the California Central Coast. LiveWire is transforming this property into the world’s first “Estate-Grown Weedery” with plans to develop it into a vertically integrated, high-end cannabis facility and wellness retreat in California. The stunning property, located in the heart of the world renown California wine country, currently houses three spacious residences, storage areas, and elaborate equestrian facilities with four barns and numerous stables. LiveWire is designing a truly unique property that features indoor and outdoor cannabis operations, including large outdoor and indoor cannabis production. Long-range plans include adding teaching and luxury recreational facilities focused on providing a comprehensive and unique cannabis-related retreat experience.

The Paso Robles Nursery

LiveWire has begun the build-out and will soon begin production in its 22,000-square-foot secure indoor cannabis nursery facility in Paso Robles, Calif. The project includes the conversion of two existing buildings with sufficient power capacity and abundant water supply. Floor plans include more than 10,000 square feet of canopy devoted to “mother” plants and separate clone storage; additional space has been identified for flowering plants. Within the two buildings, the nursery also contains research and development areas, rooms for cannabis waste and storage, record keeping and staging space, security offices, a conference room and additional designated locations required for permit approval and compliance.

LiveWire has spent significant resources to research and maneuver a complex legal environment and confirm the economic and environmental feasibility of potential LiveWire cannabis operations in different locations throughout the state of California. All LiveWire operations comply with California state law and local ordinances. To fully capitalize on these highly valuable assets, LiveWire is seeking funding to accelerate the development of its business plan.

GHC Ventures Subsidiary

GHC Ventures, LiveWire’s Coachella-based distribution division, employs a consumer-driven market approach that provides retailers access to a wide range of new high-end cannabis products, all serviced through the licensed and reliable GHC supply chain and distribution network.

GHC Ventures’ distribution network is available exclusively to licensed manufacturers that pass LiveWire’s stringent legal and environmental qualification process. This enables LiveWire to provide a large and solidly structured legal distribution network for all qualifying third-party operators in California. LiveWire is actively seeking to work with licensed operators who are enthusiastic and qualified to ensure the delivery of high-caliber and legal cannabis products for the fast-growing California medical and recreational cannabis markets.

Research Partnerships

LiveWire has established two independent research teams with world-renowned experts in their respective fields to pursue application of cannabis derivatives to specific targeted medical ailments. The company is also establishing research partnerships to explore the application of cannabinoid-based products to target specific ailments or conditions with large “sufferer” populations for both human and veterinarian applications. Possible applications may include dosing verification of zero-pesticide products for quality brands via its 7X Pure Cannabis Dosing and Verification System.

LiveWire has also engaged a highly qualified research team and advisory board to explore the opportunities in the unexplored yet highly valued equine space. The company has entered into consulting and/or advisory board agreements with high-caliber individuals from the medical and international-performance equine sector and is currently exploring strategic relationships with the veterinary departments of leading local and domestic universities and medical facilities.

7X Pure™ Dosing and Verification System

LiveWire Ergogenics is developing its “7X Pure Compliance and Dosage Verification System” intended to provide third-party verification of cannabis material origin, potency, purity, dosage and labeling, securing each product with a digital identity and clearly identifiable chain of custody.

The 7X Pure system will be completely secure, transparent and verifiable, protecting the confidentiality of growers’ and manufacturers’ intellectual property while providing retailers, consumers, government officials and others verification that the growers’ and manufacturers’ claims are true.

The system is designed as a parallel service to the seed-to-sale data provided by marijuana tracking software, will help growers and manufacturers meet increasing compliance requirements related to logistics, quality and transparency. It will also provide a high level of assurance to everyone from end users to municipalities.

Acquisitions & Operations

To maximize the utilization of its fully compliant locations and the licenses granted throughout California, LiveWire has begun and continues to pursue acquisitions of and/or strategic alliances with qualified cannabis companies and consultants. LiveWire will apply a strict regimen to the acquisition of operators, carefully utilizing its experience and legal standing in the California cannabis market for the selection of qualified operators.

Market Opportunity

Legal marijuana is the fastest-growing industry in the United States. Twenty-nine states have already legalized medical marijuana, eight states have approved it for recreational use, and more are following suit. Once the trend toward legalization expands to all 50 states, marijuana could become larger than the organic food industry, according to a new report obtained by The Huffington Post.

The U.S. marijuana industry is forecast to generate annual revenues ranging from $17 billion to $35 billion by 2021. The combined legal medical and recreational market has grown by roughly 30 percent, reaching $6 billion during 2017, according to The Marijuana Business Factbook. The same study projects the market will increase 300 percent to top $17 billion by 2021. During 2017 recreational sales grew by 80 percent, reaching $1.8 billion, not yet accounting for sales of the biggest revenue producer, California, which will only commence with recreational sales in 2018.

Business Model

LiveWire’s diligent approach to the cannabis sector is based on extensive environmental and legal research to predetermine the feasibility of the locations it selects for operations. The company pursues a carefully selected approach of acquiring, licensing and managing self-contained and permitted real estate properties for the development and distribution of its products and leasing to third party operators. LiveWire avoids the complications and high start-up cost of the typical large “growing” operations, instead focusing on becoming the market leader in research, cloning and verification, producing and distributing high quality brands.

Management Team

LiveWire’s team of experienced corporate managers and innovators are leading the company’s plans to capture increasing market share from different and often underserved market sectors in the cannabis industry. LiveWire intends to utilize its team’s experience to accelerate the development and/or acquisition of new properties, product offerings, and companies.

Bill Hodson, CEO & Chairman of the Board
Bill Hodson is responsible for the strategic direction of the firm’s development, branding, sales and marketing strategies. In addition to being responsible for the operation of the company, he leads the development and manages implementation of the company’s innovative product strategy. Previously the executive vice president of LiveWire Sports Group, Hodson was responsible for overseeing all LiveWire’s operations, including the launch of several sports publications and one of the country’s largest sports consumer expos.

As early as five years ago, Hodson recognized the potential of CBD and became an early adopter of CBD as a health and wellness supplement by including hemp-derived cannabidiol in a starburst size edible product. His experience includes not only product development, marketing and sales, but most significantly constant city and county advocacy, guiding the company through four license processes, identifying and spearheading real estate acquisitions, and to assemble operations teams comprised of nursery horticulturists, cultivators and distribution personnel. His vision for the industry is complimented with his out-of-the-box thinking and anticipation of positioning for the future.

Kyle McKay, Horticulturist
Kyle McKay is responsible for managing LiveWire’s controlled cultivation environment, developing new-age genetics to produce consistent and high-quality products for medical patients, and applying his expertise in integrated pest management with Omri-certified fungicides and pesticides. McKay oversees the company’s clone development and supervises both cultivation facilities in Coachella and Paso Robles. He also assists with location research and selection; cultivation center planning; operations set-up; and maximizing the growth potential of cannabis edibles, concentrates and oil production. McKay’s expertise in plant genetics and modern horticulture technology makes him extremely qualified to guide LiveWire’s efforts. During his 12-plus years in the cannabis horticulture field, he has grown more than 230 stable genetics, managed over 27 cultivation centers and grown the specific strains required to meet the needs of up to 45,000 medical cannabis patients at one time.

Advisory Board

Jeff Halloran, Investment Banker
Jeff Halloran is an accomplished senior-management executive with more than 35 years of experience. He has founded and held top positions in large financial and technology firms and has an outstanding record of achievement managing multimillion and billion-dollar programs. Halloran will use his standing in the Canadian markets to provide LiveWire with research and advice for potential acquisitions and strategic alliance targets in the burgeoning Canadian cannabis markets. Halloran has spent most of his career in leading management and consulting positions gathering extensive knowledge in strategic business analysis and information management theories. He served as managing director of Avalon Capital and Halloran Investment, as well as chairman and/or CEO of several companies owned by MT Dynamics. As a consulting manager he was recruited by Oracle Corporation to establish the multibillion-dollar organization’s consulting practice in Canada, eventually earning a place on the design team for Oracle Financials and its CASE Tool and Methodology. Halloran also heads up the executive committee for the Willow Breast Cancer Support Organization.

Michael Corrigan, Attorney at Law
Michael Corrigan is a legal professional at the Law Offices of Michael L. Corrigan, practicing in San Diego, Calif. His practice emphasizes general and SEC representation of emerging high-technology and other operating companies. He has been counsel to private and public companies in a broad range of industries, including computer hardware and software, telecommunications, multimedia and cannabis.

Matthew Geriak, Clinical Pharmacist and Investigational Research Pharmacist
Matthew Geriak is a specialized pharmacist and has a system-wide position on the Investigational Review Board for Sharp Healthcare, which owns five hospitals and various clinics throughout San Diego County. Sharp conducts drug research spanning from phase 1 to 4 human research clinical trials focusing on the fields of oncology, renal and heart transplantations, septic shock treatment, infectious diseases and anticoagulation. Geriak is the primary investigator for retrospective cohorts in the field of infectious diseases.

Jimmy Connors, Sports Industry Adviser
Jimmy Connors is a legendary No. 1 ranked tennis player and is considered among the greatest in the history of the sport. Today, Connors still holds three prominent Open Era Men’s singles records: 109 titles, 1,535 matches played, and 1,256 matches won. His titles include eight?majors, five U.S. Opens, two Wimbledons, one Australian Open, three year-end championships and 17?Grand Prix Super Series. Connors brings a wealth of knowledge in the sports and wellness industries that will be especially important as LiveWire expands into its next phase of development with its topical products. His decade-long exposure in the global sports world as one of the most recognized personalities adds a high level of exposure and supports LiveWire’s efforts to set itself apart in a fast-growing and still turbulent and disruptive industry.

LiveWire Ergogenics Inc. (OTC: LVVV), closed Monday's trading session at $0.00689, off by 8.0843%, on 773,683 volume with 26 trades. The average volume for the last 3 months is 1,128,306 and the stock's 52-week low/high is $0.0035/$0.037.

Recent News

• Company Files Patent for Water-Soluble CBD Delivery System
• 420 with CNW – Overwhelming Demand Causes Recreational Weed Shortage in Illinois
• Absence of Federal Regulations Exposes CBD Industry to Class Action Lawsuits

Dama Financial

The QualityStocks Daily Newsletter would like to spotlight Dama Financial.

Recent News

• Dama Financial Product Integration With PayWana Set to Revolutionize Retail Checkout Processing
• Dama Financial to Offer Free Banking Access to Eligible Cannabis-Related Businesses
• Dama Financial Enters Strategic Partnership with PayWana

InsuraGuest Inc.

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Inc..

InsuraGuest Inc. was featured today in a report by NetworkNewsWire. As an increasing number of people seek unique culture-immersive holiday experiences or simply an outlet for spending time together with far-flung family members, the luxury travel market is expected to grow with a CAGR of nearly 8 percent between 2019 and 2026, according to research by analysts at Allied Market Research (http://nnw.fm/qp9Ec).

Recent News

• InsuraGuest Inc. Fills Travelers’ Short-Term Insurance Needs in Globally Growing Tourism Markets
• InsuraGuest, Inc. Launches IG Agency in Continued Expansion of InsurTech Platform and Product Offerings
• InsuraGuest Inc. Poised to Exploit Booming European, Asian Hotel Markets through Planned Expansion